Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Drops By 17.0%

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 3,180,000 shares, a decrease of 17.0% from the February 13th total of 3,830,000 shares. Approximately 7.4% of the shares of the stock are sold short. Based on an average trading volume of 1,080,000 shares, the days-to-cover ratio is presently 2.9 days.

Hedge Funds Weigh In On BioAtla

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Magnus Financial Group LLC purchased a new position in BioAtla in the fourth quarter worth about $28,000. Two Sigma Investments LP lifted its stake in shares of BioAtla by 84.0% in the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after purchasing an additional 61,725 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after purchasing an additional 100,204 shares during the period. XTX Topco Ltd increased its position in shares of BioAtla by 7.2% during the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after purchasing an additional 10,384 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in BioAtla during the 3rd quarter valued at $623,000. 77.23% of the stock is owned by hedge funds and other institutional investors.

BioAtla Stock Performance

BCAB stock opened at $0.36 on Wednesday. The firm has a fifty day moving average price of $0.43 and a 200 day moving average price of $1.20. BioAtla has a fifty-two week low of $0.24 and a fifty-two week high of $4.02. The firm has a market cap of $17.16 million, a PE ratio of -0.21 and a beta of 1.19.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.